Andere talen Marizyme, Inc.

Aandelen

GBSX

US5703721028

Vertraagde tijd OTC Markets Andere beurzen 21:03:30 18-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,095 ^USD	0,00%		0,00%	-5,09%

06/02	Marizyme, Inc. kondigt ontslag aan van Julie Kampf uit de Raad van Bestuur	CI
2023	Marizyme, Inc. Rapporteert winstresultaten voor het derde kwartaal en de negen maanden eindigend op 30 september 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™	16/04
Marizyme, Inc. Announces Resignation of Julie Kampf from the Board of Directors	06/02
Marizyme, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Marizyme CEO Delivers Business Update	23-10-23
Marizyme CEO Delivers Business Update	23-10-23
OTC Active Stocks Watchlist (EPAZ, MRZM, GCEI, TMGI)	09-10-23
Marizyme, Inc. Announces FDA Clearance for Flagship Product, DuraGraft™	06-10-23
Marizyme, Inc. Announces FDA Clearance for Product, Duragraft	06-10-23
Marizyme, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	18-08-23
MARIZYME, INC. : Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)	24-05-23
Marizyme, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15-05-23
Marizyme, Inc. announced a financing transaction	15-05-23
MARIZYME INC : Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	10-05-23
Marizyme Announces IP Developments for DuraGraft® and Its Pipeline Products	10-05-23
Marizyme Announces IP Developments for DuraGraft® and Its Pipeline Products	10-05-23
Marizyme, Inc. Announces IP Developments for DuraGraft and its Pipeline of Products	10-05-23
Marizyme, Inc. announced that it has received $0.265216 million in funding	10-05-23
Marizyme CEO Delivers Business Update	03-05-23
MARIZYME INC Submission of Matters to a Vote of Security Holders (form 8-K/A)	26-04-23
MARIZYME INC : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)	20-04-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Marizyme, Inc.

Aandelen

GBSX

US5703721028

Andere talen

Filters